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〈Letter to the Editor〉
   Nivolumab is an immune checkpoint inhibitor 
directly targeting a negative immunoregulatory 
molecule of T cells, programmed cell death protein 
1 (PD-1), with anti-tumor immune activity.The 
clinical benefits from anti-PD-1 antibodies against 
melanoma is quite remarkable. However, various 
immune-related adverse events (irAEs), such 
as interstitial pneumonia, have been reported１）. 
Grade3-4 irAEs were observed in 11.7%１）, and 
9.9%２） of nivolumab-treated melanoma patients１）. 
Myasthenia gravis (MG) is an autoimmune disease 
mediated by B-cells, which affects neuromuscular 
junctions. Anti-acetylcholine receptor antibodies 
(AChR-Ab) are highly specific for diagnosis３）. 
Several cases of the onset of MG by anti PD-1 
antibody have been reported４－８）. Here, we report 
a case that a patient with melanoma developed MG 
after the second administration of nivolumab. The 
metastatic melanoma was successfully controlled by 
reinstituting nivolumab in combination with a low 
dose of corticosteroids.
   A woman in her 70s presented with malignant 
melanoma in the middle of the lumbar region. 
Primary resection and sentinel lymph node (SLN) 
biopsy were performed. Pathologically, right 
inguinal SLN metastasis was positive. Then, 
right inguinal lymph node dissection (LND) 
was performed. Postoperatively, interferon beta 
treatment was initiated as an adjuvant therapy. 
Approximately 5 months after surgery, several 
subcutaneous, in-transit and lymph node metastasis 
were observed. After possible resection of these 
metastatic lesions, nivolumab therapy was started 
with a dose of 2 mg/kg every 3 weeks. Focal 
adjustment disorder appeared around 10 days after 
the second administration, then ptosis (Fig. 1) and 
muscle weakness were observed. AChR-Ab was 
elevated to 4.0 nmol/L (normal range ≤0.2 nmol/L). 
In addition, single fiber electromyography study 
was positive because of increased jitter in the 
frontalis muscle. MG was diagnosed. Nivolumab 
administration was discontinued and daily oral 
administration of 10 mg of prednisolone (PSL) and 
anticholinesterase drug was started, followed by 
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improvement of the symptoms. Because lymph node 
metastasis gradually worsened, administration of 2 
mg/kg of nivolumab every 3 weeks was reinstituted 
on the 158th day from the second administration in 
combination with PSL 10 mg daily. Since recurrence 
of MG was not observed, PSL was reduced to 5mg 
after the second restart. Due to that the patient 
complained discomfort of the eyelids after several 
weeks, the dose of PSL was increased again to 10 
mg. After that, nivolumab treatment was able to be 
continued every 3 weeks. Lymph node enlargement 
was controlled, and the patient had a stable disease 
state for about 18 months. Fig. 2 summarizes the 
clinical course. 
   In this case, AChR-Ab was slightly elevated to 
1.6 nmol/L using her serum before nivolumab 
administration in the retrospective examination. 
Similar cases of MG with AChR-Ab subclinically 
before nivolumab therapy had been reported７，８）. 
Sakthivel P et al. showed that an expression of 
PD-1 on T cells and its ligand PD-L1 on monocytes 
was elevated in MG patients and suggested that 
PD-1 and PD-L1 might have a regulatory role 
behind autoimmune human MG９）. By disrupting 
interaction between PD-1 and its ligands, it is 
assumed that nivolumab induced T-cell activation, 
resulting in elevation of AChR-Ab and consequently 
induced MG. There is no specific and general 
method to solve a dilemma related to reinstitution 
of nivolumab in serious irAE cases. The method 
Figure１
Fig. 1 Bilateral ptosis 24 days after the second treatment of nivolumab
Fig. 2 The summary of the clinical course
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employed should be determined according to 
severity of MG in each case, because different 
clinically severe, prolonged, and even fatal case has 
been reported７）. We demonstrated a method which 
was able to resume nivolumab without regression 
of MG in combination with PSL 10 mg daily. 
Although attenuation of the effect of nivolumab 
by corticosteroids is possible, the development of 
tumor was suppressed and the effect of nivolumab 
has been preserved in this case. Even if nivolumab 
therapy is forced to be discontinued in irAE cases, 
it is worth considering reinstitution of it with 
prednisolone in combination.
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